Isoxazoline is a relatively new chemical family of five-membered heterocyclic chemical compounds with one oxygen and one nitrogen atom next to each other. Isoxazoline compounds such as fluralaner, afoxolaner, sarolaner, and lotilaner are active components in tick repellents.
Ticks are non-flying insects that are parasites on dogs, cats, and other animals. The host must come into direct touch with a tick in order to become a parasite. Ticks are dangerous to pets because they transmit illnesses such as Lyme disease, Rocky Mountain spotted fever, ehrlichiosis, tularaemia, and STARI (Southern tick-associated rash illness). In order for illnesses to be transferred, a tick must remain attached to a host for several hours. To prevent pets against tick bites, a variety of repellents, insecticides, and growth inhibitors are commercially available.
The isoxazoline class of medicines are oral insecticides that have been approved for the treatment of ectoparasites in companion animals such as dogs and cats. These medications were initially introduced in 2013 as veterinary treatments for ticks and fleas in dogs. Several studies, however, have demonstrated their effectiveness against various veterinary and agricultural parasites. Bravecto, Credlio, Nexgard, and Simparica are examples of FDA-approved isoxazoline medications.
The US FDA has authorised these medications for tick and flea infestation. Some are also licenced for the treatment of gastrointestinal parasite infections and ear mite management. These medications are either consumed or given topically. The majority of active substances were first launched for crop protection and thereafter for companion animals.
Innovations on current medications for new indications in oral and topical formulations, as well as increased awareness of ectoparasite prevention and control of fleas and ticks, are expected to drive market expansion. The market is divided into three sections: product type, pet kind, and geography.
North America: 5,603million USD (2030 value); CAGR: 18.1%
Get more information on this report Download Sample Report
Pet owners are stockpiling consumables and prescriptions for their cats and dogs as a result of the COVID-19 (coronavirus) epidemic. Companies in the Isoxazoline industry in the United States have reinforced their supply chains in order to weather demand fluctuations. The FDA (Food and Drug Administration) has authorised a unique combination Isoxazoline parasite preventative for dogs in the United States, according to the most recent veterinary news. This has provided new potential for firms in the Isoxazoline market in the United States.
During the projected period, the US isoxazoline drugs market is expected to grow at a positive CAGR of 18.1%. Many pet owners, however, are seeing medication resistance difficulties in their cats and dogs. As a result, innovative resistance-breaking antiparasitics with unique mechanisms/modes of action are required. To enhance the availability of effective therapies, pharmaceutical companies must invest in innovative modalities such as parasite vaccinations or environmentally friendly approaches. Companies in the US isoxazoline market are investing more in R&D in oxime-participating cyclization strategies for the development of effective molecules.
The stringency of laws and regulations for isoxazoline-based medications provided to companion animals such as dogs and cats is rising. The United States Food and Drug Administration (FDA) established a Center for Veterinary Medicine (CVM) to approve medications for use in animals, including isoxazoline-based products. The Environmental Protection Agency (EPA), like the FDA, regulates isoxazoline-based products used in animals. In general, an animal medicine (including isoxazoline) must be authorised by the FDA before it may be sold commercially in the United States. Before the animal product may be commercialised, it must be registered with the EPA. The Environmental Protection Agency (EPA) has developed rules and regulations to govern the marketing of spot-on Isoxazoline-based tick repellent products in the United States. As a result, increased government controls on Isoxazoline-based tick repellents are projected to be a key restraint for Isoxazoline-based product makers.
Globally, India is a fast increasing market for pet care goods. People in the country are adopting pets due to an increase in disposable income and rising urbanisation. There are around 19 million pets in India, with dogs accounting for 80 percent of the total, followed by cats and smaller animals such as fish and birds. Every year, over 600,000 pets are adopted in India. The absence of regional isoxazoline producers in China and India presents considerable prospects for US-based manufacturers. Boehringer Ingelheim International GmbH will offer NexGard and Broadline brands of isoxazoline-based tick/flea repellent in India in July 2020. These factors are projected to give profitable possibilities for US-based firms such as Merck Animal Health Inc., Elanco Animal Health Incorporated, and Zoetis Inc. to export their products to China and India.
Based on product type, the worldwide isoxazoline drugs market is divided into fluralaner, sarolaner, lotilaner, and afoxolaner. In 2021, afoxolaner medicines sold more than any other drug on the market, and they had the biggest market share.
The market is divided into two categories: dogs and cats. During the years 2020–2021, the number of dogs and cats adopted skyrocketed. According to a poll performed by the Humane Society of the United States, over half of all American households own at least one dog. The dogs' category took the bulk of the market share in 2021 and is predicted to increase at a CAGR of 18.11 percent during the forecast period.
Country wise Growth Insights Request Sample Pages
In 2021, the Americas will have the highest share of the isoxazoline medicines market, with a CAGR of 18.16 percent during the projected period. One of the primary reasons driving the market's growth is the rising number of medication approvals and greater adoption rate.
The US FDA approved a new label indication for Simparica Trio (sarolaner, moxidectin, and pyrantel chewable tablets) for the treatment of tick infestation in dogs in January 2022.
Elanco introduced Credelio Plus, a chewy monthly pill for treating fleas, worms, and ticks in dogs, in June 2021.
Elanco launched Credelio CAT, an oral tick and flea treatment for cats, in May 2021. Within 6 hours, this medication begins killing fleas.
In May 2021, Zoetis announced that the US Food and Drug Administration has authorised a new label for Simparica chewables to prevent Borrelia burgdorferi infections in dogs aged six months and up.
BRAVECTO (fluralaner) 1-MONTH Chews for dogs and puppies eight weeks of age and older were approved by the US FDA in July 2020. This medication is used to treat and prevent flea and tick infestations in dogs and cats (Ixodes scapularis, Dermacentor variabilis, and Rhipicephalus sanguineus). It can also be used to treat and manage Amblyomma americanum (lone star tick).
Simparica Trio, which protects against fleas and ticks, heartworms, roundworms, and hookworms, was approved by the US FDA in February 2020.
Merck Animal Health launched BRAVECTO Cares, an educational campaign, in May of this year. They used this ad to highlight the essential function that service dogs serve and the significance of keeping them healthy, which includes tick and flea protection.